Key Points
- CEO Ian Mortimer sold shares: Mortimer sold 7,308 shares on March 13 for $403,620.84, reducing his holdings by 26.84% to 19,923 shares after several earlier open‑market sales (including 270,000 shares on March 9 for ~$16.29M).
- Clinical and analyst momentum: Xenon completed the X‑TOLE2 Phase‑3 study for XEN1101, prompting multiple analyst upgrades and a consensus Buy rating with a consensus price target of about $71.94.
- Balance‑sheet and dilution tradeoff: The company raised roughly $747.5M in an upsized public offering, extending runway but increasing outstanding shares and near‑term dilution risk while institutional ownership remains very high (~95%).
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) insider Andrea Difabio sold 1,342 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $74,118.66. Following the sale, the insider owned 7,301 shares of the company's stock, valued at $403,234.23. This trade represents a 15.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrea Difabio also recently made the following trade(s):
- On Tuesday, March 10th, Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total transaction of $156,706.77.
Xenon Pharmaceuticals Trading Down 4.6%
Shares of Xenon Pharmaceuticals stock opened at $55.23 on Friday. The stock has a market capitalization of $4.59 billion, a price-to-earnings ratio of -12.67 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95. The firm's 50-day moving average price is $43.71 and its two-hundred day moving average price is $41.92.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the company posted ($0.84) EPS. As a group, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
More Xenon Pharmaceuticals News
Here are the key news stories impacting Xenon Pharmaceuticals this week:
- Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
- Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
- Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
- Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
- Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
- Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
- Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
- Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals during the 2nd quarter worth $56,637,000. Wellington Management Group LLP increased its stake in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock valued at $144,936,000 after buying an additional 1,435,096 shares during the period. Geode Capital Management LLC raised its position in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company's stock worth $30,369,000 after acquiring an additional 900,746 shares during the last quarter. Braidwell LP raised its position in shares of Xenon Pharmaceuticals by 33.0% during the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company's stock worth $112,837,000 after acquiring an additional 895,154 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Xenon Pharmaceuticals by 1,968.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company's stock valued at $38,650,000 after acquiring an additional 820,608 shares during the period. Institutional investors own 95.45% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have issued reports on XENE shares. Needham & Company LLC lifted their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a report on Monday. Bank of America restated a "buy" rating on shares of Xenon Pharmaceuticals in a research note on Monday. JPMorgan Chase & Co. lifted their price target on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a report on Friday, January 9th. Finally, Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $71.94.
Get Our Latest Stock Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company's pipeline comprises multiple preclinical and clinical programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
